Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EYEM finally resuming its move up. Now at .024 +20%. Jim
Customer Service - wood my 3 dvd Larry Sanders is 13 episodes. I will send them back today having watched only a couple of episodes. Had I known it would tie up my future requests, I would not have ordered it. Leason leaned. Don't order multi dvd movies/shows. They just restrict the ability to get other dvds. If I mail them back today, I would expect at least a week before getting my next dvd. That sucks. BTW when requesting the Larry Sanders 1st season dvds, no indication was made on how many dvds were included. That info should be provided. Since my trial period has been extended, I will not complain. Jim
Customer service note - beware of multi dvd requests. My email and their response explains all.
-------Original Message-------
From: XXXX
Date: 04/15/04 15:32:25
To: memberhelp@gameznflix.com
Subject: Re: Thanks for trying our service. Currently, the programming staff is uploading the new game data base.
Customer service,
I have a queued DVD that has not shipped in the 2 weeks since I requested it. Another request was sent even though it was placed behind the DVD I wanted. The DVD sent was a season of Larry Sanders. This contained 3 DVDs. I got that about a week ago and the other DVD (Somethings Gotta Give) has not been sent. Does the 3 DVD set count as my 3 limit at one time or is it considered as one movie out?
Your explanation of the policy would be appreciated.
Jim
REPLY (not to wordy)
Yes the set does = 3.
Member Support
GameZnFlix, Inc.
ETCR continues great move of the last week or so. Now at .05. Was at .02 a few days ago. Nice steady climb. Something may be up. Anyone else in this one? Jim
Thata boy. That is what I am doing. Plan to sell on penny increments until all gone or stock is worthless. Not costing me anything. Jim
ACMM watch. This one has moved from .02 to .145 in the last six months. Its pink and lightly traded. Be careful. Jim
ACMM watch. This one has moved from .02 to .145 in the last six months. Its pink and lightly traded. Be careful. Jim
d this is a test to see who has the balls to stick a good shake out. Jim
dk you buying on this shake? Jim
LFP starting to pop on decent volume. Now at .41 +8%. This one is due.
TCOW moving too. Now up 15% from lod. Jim
LFP starting to pop on decent volume. Now at .41 +8%. This one is due. Jim
TCOW up to .74 +4% for day and 10% from lod. Jim
dk pps holding well in the down market. Hopefully, FO will stay silent a few more days so the price can go up a little more. <G> Jim
EYEM dragging its feet today. Jim
VRA may bounce on news. Thursday April 15, 9:52 am ET
PLANTATION, Fla., April 15 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA - News) and Viragen International, Inc. (OTC Bulletin Board: VGNI - News) today announced that Viragen (Scotland) Ltd. has been awarded a prestigious Grant from the Scottish government for the approximate sum of 466,000 pounds sterling ($833,000) for the purpose of supporting the research and development of its anti-CD55 Antibody, a monoclonal antibody designed for the treatment of a broad range of cancers, either alone or in combination with other anti- cancer antibodies.
"The Scottish Executive awarded Viragen's CD55 Project the maximum dollar amount eligible to be granted by its 'SPUR Plus' program," stated Dr. Karen Jervis, Viragen's Director of Technology and Projects Coordinator. "These grants are designed to reward Scotland's most promising and innovative research programs, and we are very pleased to be recognized with this funding. We believe the anti-CD55 Antibody represents a novel and powerful approach to cancer therapy by deactivating the tumor's defense mechanism, thus allowing other anti-cancer antibodies to work better, or itself stimulating the immune system to target and kill cancer cells."
Anti-CD55 Antibody Project:
In collaboration with Cancer Research UK and the University of Nottingham (England), Viragen is developing a monoclonal antibody designed to block the protective effect of the protein CD55 on the surface of tumor cells. The protein CD55 is one of a number of proteins which protect normal healthy cells from being destroyed by the complement system, part of the human immune response against disease. The problem arises when cancer cells also express this control protein to camouflage and protect themselves from the immune system.
The anti-CD55 antibody is designed to remove the tumor's protective mechanism and, in theory, may boost patient response rates either as a stand- alone therapy or in combination with other antibodies. Viragen holds an option from Cancer Research Technology Limited to acquire an exclusive worldwide license to this platform technology with potential applications in a large number of cancer types.
About Cancer Research Technology Limited:
Cancer Research Technology Limited (CRT) is a specialist technology transfer and development company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies.
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen's strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the biopharmaceutical industry.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen (Scotland) Ltd. is a wholly owned subsidiary of Viragen International. Viragen's key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America's Blood Centers and the German Red Cross.
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746
Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expect", "potential", "suggests", "may", "will", "should", "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
--------------------------------------------------------------------------------
Source: Viragen, Inc.
VRA may bounce on news. Thursday April 15, 9:52 am ET
PLANTATION, Fla., April 15 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA - News) and Viragen International, Inc. (OTC Bulletin Board: VGNI - News) today announced that Viragen (Scotland) Ltd. has been awarded a prestigious Grant from the Scottish government for the approximate sum of 466,000 pounds sterling ($833,000) for the purpose of supporting the research and development of its anti-CD55 Antibody, a monoclonal antibody designed for the treatment of a broad range of cancers, either alone or in combination with other anti- cancer antibodies.
"The Scottish Executive awarded Viragen's CD55 Project the maximum dollar amount eligible to be granted by its 'SPUR Plus' program," stated Dr. Karen Jervis, Viragen's Director of Technology and Projects Coordinator. "These grants are designed to reward Scotland's most promising and innovative research programs, and we are very pleased to be recognized with this funding. We believe the anti-CD55 Antibody represents a novel and powerful approach to cancer therapy by deactivating the tumor's defense mechanism, thus allowing other anti-cancer antibodies to work better, or itself stimulating the immune system to target and kill cancer cells."
Anti-CD55 Antibody Project:
In collaboration with Cancer Research UK and the University of Nottingham (England), Viragen is developing a monoclonal antibody designed to block the protective effect of the protein CD55 on the surface of tumor cells. The protein CD55 is one of a number of proteins which protect normal healthy cells from being destroyed by the complement system, part of the human immune response against disease. The problem arises when cancer cells also express this control protein to camouflage and protect themselves from the immune system.
The anti-CD55 antibody is designed to remove the tumor's protective mechanism and, in theory, may boost patient response rates either as a stand- alone therapy or in combination with other antibodies. Viragen holds an option from Cancer Research Technology Limited to acquire an exclusive worldwide license to this platform technology with potential applications in a large number of cancer types.
About Cancer Research Technology Limited:
Cancer Research Technology Limited (CRT) is a specialist technology transfer and development company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies.
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon, monoclonal antibodies, peptide drugs and therapeutic vaccines. Viragen's strategy also includes the development of Avian Transgenic Technology for the large-scale, cost-effective manufacturing of its portfolio of protein-based drugs, as well as offering Contract Manufacturing for the biopharmaceutical industry.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's majority owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen (Scotland) Ltd. is a wholly owned subsidiary of Viragen International. Viragen's key partners and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, Cancer Research UK, University of Nottingham (U.K.), University of Miami, America's Blood Centers and the German Red Cross.
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746
Fax: (954) 233-1414
E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "expect", "potential", "suggests", "may", "will", "should", "could" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
--------------------------------------------------------------------------------
Source: Viragen, Inc.
GZFX - nice start this morning. Up 13% on over 2.6 million shares. Jim
GZFX - nice start this morning. Up 10% on over 1.6 million shares. Jim
GZFX - nice start this morning. Up 10% on over 1.6 million shares. Jim
GZFX - nice start this morning. Up 10% on over 1.6 million shares. Jim
GZFX - nice start this morning. Up 10% on over 1.6 million shares. Jim
Good PR - Email just sent to me.
Dear Trial Members,
Thanks for trying our service. Currently, the programming staff is uploading the new game data base. This should be finished by the end of the coming weekend. At this time, I have directed the accounting department to NOT charge anyone until the new game data base is up and running. After the new game data base is up and running GameZnFlix will start the Trial Period for all of those who have already joined. At that time, an e-mail will be sent to all those on the trial basis to inform you that the period has begun.
Until then we ask that you try the DVD service and please allow for the company’s growing pains.
Thanks
John Fleming, CEO/President
ECGI back over a buck. Huge volume today. Think I will hold until pm tomorrow. Just may be some news coming. Jim
ECGI back over a buck. Huge volume today. Think I will hold until pm tomorrow. Just may be some news coming. Jim
ECGI trying to regain momentum. Back to .98 +18%. Jim
ECGI trying to regain momentum. Back to .98 +18%. Jim
Hang in there folks. Just a little mm tree shaking here. I would guess it will be back over .02 by the end of day. Jim
RCO coming back from the dead. Just jumped from .56 to .62. Good volume too. Jim
RCO coming back from the dead. Just jumped from .56 to .62. Good volume too. Jim
TCOW and SEHO looking good. Jim
QBID unreal pinky. Up another 80%. Go figure. Jim
Volume down today but ETCR move the last few sessions continues. Now up 12.5% to .045. Jim
Volume down today but ETCR move the last few sessions continues. Now up 12.5% to .045. Jim
Volume down today but ETCR move the last few sessions continues. Now up 12.5% to .045. Jim
Volume down today but ETCR move the last few sessions continues. Now up 12.5% to .045. Jim
Volume down today but ETCR move the last few sessions continues. Now up 12.5% to .045. Jim
SNKI trading today. Usually does not trade at all. May be worth watching. Now at .28 +40%. Jim
SNKI trading today. Usually does not trade at all. May be worth watching. Now at .28 +40%. Jim
SEHO time to buy more. Unreal the retracement. Now at .48 after getting to .74.
Its in the hot security sector. Here is profile info - Sense Holdings, Inc. designs, develops, manufactures and sells products that use biometric technology to verify a person's identity. The Company has integrated smartcard technology into its biometric applications. Applications, such as time and attendance and access control, are developed around the biometric identification technology and smartcard technology. The Company is also a research and development company specializing in biometric security and explosive detection. Its subsidiary, Micro Sensor Technologies, Inc., is exclusively engaged in the acquisition and development of explosive detection technology.
SEHO time to buy more. Unreal the retracement. Now at .48 after getting to .74.
Its in the hot security sector. Here is profile info - Sense Holdings, Inc. designs, develops, manufactures and sells products that use biometric technology to verify a person's identity. The Company has integrated smartcard technology into its biometric applications. Applications, such as time and attendance and access control, are developed around the biometric identification technology and smartcard technology. The Company is also a research and development company specializing in biometric security and explosive detection. Its subsidiary, Micro Sensor Technologies, Inc., is exclusively engaged in the acquisition and development of explosive detection technology.